Skip to main content

Proteomics, Genomics Projects among 131 Komen Foundation Grants

NEW YORK, June 9 - Genomics- and proteomics-related breast cancer research projects are among 131 grants totaling $21 million awarded by the Susan G. Komen Breast Cancer Foundation for fiscal year 2003.


The foundation announced the recipients of the grants during its Sixth Annual Mission Conference, held in Washington, DC, today.


The Komen Foundation Award and Research Grant Program is funded by 25 percent of all proceeds raised by Komen Affiliates and Komen Race for the Cure events across the country, as well as by private and corporate donations. Funds for the FY 2003 grants were raised over the course of 2002.


Some genomics and proteomics research projects supported by this year's grants include:


·         $249,956 for "Capture breast cancer early: Detecting ductal carcinoma in situ by serum proteomic analysis using ProteinChip arrays and SELDI-mass spectrometry," Jinong Li, Department of Pathology, Johns Hopkins University.

·         $250,000 for "Prospective study of the predictive power of surface-enhanced laser desorption ionization mass spectrometry in detecting early stage breast cancer," Peter Oefner, Stanford Genome Technology Center.

·         $250,000 for "Identification of Markers of Aggressive Breast Cancer by Large Cohort Tissue Microarrays," Harriet Kluger, Yale University.

·         $135,000 for "Identification and Characterization of Novel RAD6 Group Genes and Their Role in Genome Stability," Floyd Romesberg, Scripps Research Institute.


A complete list of FY 2003 grant recipients is available here.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.